Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Elizabeth Sakach"'
Autor:
Kevin Kalinsky, Melissa K. Accordino, Codruta Chiuzan, Prabhjot S. Mundi, Elizabeth Sakach, Claire Sathe, Heejoon Ahn, Meghna S. Trivedi, Yelena Novik, Amy Tiersten, George Raptis, Lea N. Baer, Sun Y. Oh, Amelia B. Zelnak, Kari B. Wisinski, Eleni Andreopoulou, William J. Gradishar, Erica Stringer-Reasor, Sonya A. Reid, Anne O'Dea, Ruth O'Regan, Katherine D. Crew, Dawn L. Hershman
Publikováno v:
Journal of Clinical Oncology.
PURPOSE Cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) with endocrine therapy (ET) improves progression-free survival (PFS) and overall survival (OS) in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aed64fc0fc65b36fd4113a68efc0e7db
https://doi.org/10.1200/jco.22.02392
https://doi.org/10.1200/jco.22.02392
Publikováno v:
Cancers. 14(23)
The emergence of Trop-2 as a therapeutic target has given rise to new treatment paradigms for the treatment of patients with advanced and metastatic breast cancer. Trop-2 is most highly expressed in triple negative breast cancer (TNBC), but the recep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09bc0f8cd746cc031039857ada03639d
https://pubmed.ncbi.nlm.nih.gov/36497418
https://pubmed.ncbi.nlm.nih.gov/36497418
Publikováno v:
Clinical breast cancer. 21(6)
Triple negative breast cancer (TNBC) represents 15% to 20% of all primary breast cancers and is the most aggressive subtype of breast cancer. There has been rapid progress in targeted therapy and biomarker development to identify the optimal treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01465a3d2df89774a62005b1f81eeaab
https://pubmed.ncbi.nlm.nih.gov/34629314
https://pubmed.ncbi.nlm.nih.gov/34629314
Autor:
Amber Draper, Olatunji B. Alese, Elizabeth Sakach, Urvi Patel, Mehmet Akce, Stephen Szabo, Christina Wu, Christine C. Davis, Bassel El-Rayes, Subir Goyal, Marley L Watson, Evan Bryson, Walid L. Shaib, Kevin Hall
Publikováno v:
Clinical colorectal cancer. 20(2)
The administration schedule of capecitabine for the treatment of metastatic colorectal cancer (mCRC) in clinical trials has been 14 days of drug with 7 days off in a 21 day cycle (14/7). In an effort to improve tolerability, an alternative every othe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f0757357f4fd62e7e9200b2a62b1a10
https://pubmed.ncbi.nlm.nih.gov/33975781
https://pubmed.ncbi.nlm.nih.gov/33975781
Autor:
Elizabeth Sakach, Yichun Cao, Ryan Mooney, Caitlin E. Taylor, Christine R. Tallo, Yuan Liu, Jane L. Meisel
Publikováno v:
Journal of Clinical Oncology. 39:10588-10588
10588 Background: Testing for mutations in BRCA1 and BRCA2 is recommended for all women with ovarian cancer (OC), given important implications for treatment and prognosis. Despite this recommendation, studies show that only a small percentage of OC p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de12c086bb829dc3f3d109c79c5b26b8
https://doi.org/10.1200/jco.2021.39.15_suppl.10588
https://doi.org/10.1200/jco.2021.39.15_suppl.10588
Autor:
Kristina Frinzi, Meagan Spencer Barbee, Urvi Patel, Elizabeth Sakach, Zhengjia Chen, Jane L. Meisel
Publikováno v:
Journal of Clinical Oncology. 37:1062-1062
1062 Background: Cyclin-dependent kinase 4/6 inhibitors (CDK 4/6i) are widely used in the treatment of hormone receptor positive, metastatic breast cancer (MBC). CDK 4/6is are well-tolerated and highly effective, but can cause neutropenia. Therefore,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8427dbf9d08ebc2d9d78160191055bbc
https://doi.org/10.1200/jco.2019.37.15_suppl.1062
https://doi.org/10.1200/jco.2019.37.15_suppl.1062